Canagliflozin protects diabetic cardiomyopathy by mitigating fibrosis and preserving the myocardial integrity with improved mitochondrial function
Deepika Dasari, Srashti Goyal, Anuhya Penmetsa, Dharmarajan Sriram, Arti Dhar
Topics & Concepts
CanagliflozinDiabetic cardiomyopathyMedicineFibrosisPharmacologyCardiomyopathyDiabetes mellitusInternal medicineEndocrinologyType 2 diabetesCardiac fibrosisHeart failureDiabetes Treatment and ManagementCardiovascular Function and Risk FactorsPancreatic function and diabetes